The lancet oncology
-
The lancet oncology · Oct 2019
Comparative StudyFour-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We aimed to evaluate the long-term benefit of nivolumab and the effect of response and disease control on subsequent survival. ⋯ Bristol-Myers Squibb.